Prescription of high-potency corticosteroid agents and clotrimazole- betamethasone dipropionate by pediatricians

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1725-1731

  Fleischer Jr , Alan B ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal agent; Clotrimazole betamethasone dipropionate; Dermatitis; Fungal infection; Pediatrics; Topical corticosteroid

Indexed keywords

BETAMETHASONE; CLOTRIMAZOLE; CORTICOSTEROID;

ARTICLE; CANDIDIASIS; CHILDHOOD DISEASE; COMBINATION CHEMOTHERAPY; DIAPER DERMATITIS; DRUG POTENCY; DRUG USE; ERYTHEMATOSQUAMOUS SKIN DISEASE; HUMAN; MEDICAL PRACTICE; PEDIATRICIAN; PRESCRIPTION; SKIN ATROPHY; SKIN DISEASE; STEROID THERAPY; TOPICAL DRUG ADMINISTRATION;

EID: 0032716429     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80051-4     Document Type: Article

References (16)

1. Krowchuk DP, Bradham DD, Fleischer AB Jr. Dermatologic services provided to children and adolescents by primary care and other physicians in the United States. Pediatr Dermatol. 1994;11:199-203.
2. Smith ES, Fleischer AB Jr, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: An analysis of office visits for cutaneous fungal infections, 1990-1994. J Am Acad Dermatol. 1998; 39:43-47.
3. Lotrisone® product information. In: Physicians' Desk Reference®, 51st ed. Montvale, NJ: Medical Economics Co., Inc.; 1997: 2515-2516.
4. Tenney JB, White KL, Williamson JW. National Ambulatory Medical Care Survey: Background and Methodology. Hyattsville, Md: National Center for Health Statistics, Vital and Health Statistics; 1974:2.
5. 1990 National Ambulatory Medical Care Survey, public use data tape documentation. Hyattsville, Md: US Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1992.
6. National Ambulatory Medical Care Survey. Relative SE documentation. Available at: ftp:///ftp.cdc.gov/pub/Health_ Statistics/NCHS/Dataset_Documentation/ NAMCS/.
7. Stoughton RB. Vasoconstrictor assay-specific applications. In: Maibach HI, Surber C, eds. Topical Corticosteroids. Basel, Switzerland: Karger; 1992:42-53.
8. Pershing LK, Corlett J, Lambert L, et al. There are three not seven potency classes of topical corticosteroids. J Invest Dermatol. 1994;102:600. Abstract.
9. Harper J. Topical corticosteroids for skin disorders in infants and children. Drugs. 1988;(Suppl 5):34-37.
10. Boiko S. Treatment of diaper dermatitis. Dermatol Clin. 1999;17:235-240.
11. Sires UI, Mallory SB. Diaper dermatitis. How to treat and prevent. Postgrad Med. 1995;98:79-84,86.
12. Jethwa K. Nappy rash: A pharmaceutical approach. Prof Care Mother Child. 1994; 4:219-220.
13. Katz HI, Bard J, Cole GW, et al. SCH 370 (clotrimazole-betamethasone dipropionate) cream in patients with tinea cruris or tinea corporis. Cutis. 1984;34:183-188.
14. Evans EGV, James IGV, Seaman RAJ, Richardson MD. Does naftifine have antiinflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol. 1993;129:437-442.
15. Millikan LE, Galen WK, Gewirtzman GB, et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol. 1988;18:52-56.
16. Fleischer AB Jr. Lotrisone...a negative report. The Schoch Letter. 1993;43:11. Letter.